BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Galmiche A, Chauffert B, Barbare JC. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett 2014;346:159-62. [PMID: 24380851 DOI: 10.1016/j.canlet.2013.12.028] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Houessinon A, Gicquel A, Bochereau F, Louandre C, Nyga R, Godin C, Degonville J, Fournier E, Saidak Z, Drullion C, Barbare J, Chauffert B, François C, Pluquet O, Galmiche A. Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib. Cancer Letters 2016;370:242-9. [DOI: 10.1016/j.canlet.2015.10.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
2 Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, Yu H, Lin H, Cai X. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Letters 2015;367:1-11. [DOI: 10.1016/j.canlet.2015.06.019] [Cited by in Crossref: 111] [Cited by in F6Publishing: 121] [Article Influence: 15.9] [Reference Citation Analysis]
3 Facciorusso A, Licinio R, Carr BI, Di Leo A, Barone M. MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2015;9:993-1003. [PMID: 25915713 DOI: 10.1586/17474124.2015.1040763] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
4 Chen W, Xiao W, Zhang K, Yin X, Lai J, Liang L, Chen D. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. Sci Rep 2016;6:22976. [PMID: 26964667 DOI: 10.1038/srep22976] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
5 Yang PM, Lin LS, Liu TP. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Biomolecules 2020;10:E117. [PMID: 31936661 DOI: 10.3390/biom10010117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
6 Ren J, Chen GG, Liu Y, Su X, Hu B, Leung BC, Wang Y, Ho RL, Yang S, Lu G, Lee CG, Lai PB. Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma. PLoS One 2016;11:e0153863. [PMID: 27093553 DOI: 10.1371/journal.pone.0153863] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
7 Lu Y, Chan YT, Tan HY, Zhang C, Guo W, Xu Y, Sharma R, Chen ZS, Zheng YC, Wang N, Feng Y. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. J Exp Clin Cancer Res 2022;41:3. [PMID: 34980204 DOI: 10.1186/s13046-021-02208-x] [Reference Citation Analysis]
8 Yao F, Deng Y, Zhao Y, Mei Y, Zhang Y, Liu X, Martinez C, Su X, Rosato RR, Teng H, Hang Q, Yap S, Chen D, Wang Y, Chen MM, Zhang M, Liang H, Xie D, Chen X, Zhu H, Chang JC, You MJ, Sun Y, Gan B, Ma L. A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nat Commun 2021;12:7333. [PMID: 34921145 DOI: 10.1038/s41467-021-27452-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Diederich M, Cerella C. Non-canonical programmed cell death mechanisms triggered by natural compounds. Semin Cancer Biol 2016;40-41:4-34. [PMID: 27262793 DOI: 10.1016/j.semcancer.2016.06.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
10 Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, de Frutos PG, Reig M, Fernandez-Checa JC, Marí M, Colell A, Bruix J, Morales A. Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Oncotarget 2018;9:16701-17. [PMID: 29682179 DOI: 10.18632/oncotarget.24673] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
11 Peng HS, Liao MB, Zhang MY, Xie Y, Xu L, Zhang YJ, Zheng XF, Wang HY, Chen YF. Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells. PLoS One 2014;9:e100814. [PMID: 24956259 DOI: 10.1371/journal.pone.0100814] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
12 Lu B, Chen XB, Ying MD, He QJ, Cao J, Yang B. The Role of Ferroptosis in Cancer Development and Treatment Response. Front Pharmacol 2017;8:992. [PMID: 29375387 DOI: 10.3389/fphar.2017.00992] [Cited by in Crossref: 110] [Cited by in F6Publishing: 115] [Article Influence: 27.5] [Reference Citation Analysis]
13 Galmiche A, Diouf M, Barbare JC. The endless SEARCH for a better medical treatment of advanced hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2015;39:535-7. [PMID: 25861864 DOI: 10.1016/j.clinre.2015.02.006] [Reference Citation Analysis]
14 Zheng M, Xu H, Liao XH, Chen CP, Zhang AL, Lu W, Wang L, Yang D, Wang J, Liu H, Zhou XZ, Lu KP. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. Oncotarget 2017;8:29771-84. [PMID: 28404959 DOI: 10.18632/oncotarget.15967] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
15 Liu Y, Zhang X, Zhang J, Tan J, Li J, Song Z. Development and Validation of a Combined Ferroptosis and Immune Prognostic Classifier for Hepatocellular Carcinoma. Front Cell Dev Biol 2020;8:596679. [PMID: 33425905 DOI: 10.3389/fcell.2020.596679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
16 Younis NS, Ghanim AMH, Saber S. Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. Sci Rep 2019;9:19095. [PMID: 31836811 DOI: 10.1038/s41598-019-55666-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
17 Liu T, Liu W, Zhang M, Yu W, Gao F, Li C, Wang SB, Feng J, Zhang XZ. Ferrous-Supply-Regeneration Nanoengineering for Cancer-Cell-Specific Ferroptosis in Combination with Imaging-Guided Photodynamic Therapy. ACS Nano 2018;12:12181-92. [PMID: 30458111 DOI: 10.1021/acsnano.8b05860] [Cited by in Crossref: 138] [Cited by in F6Publishing: 126] [Article Influence: 34.5] [Reference Citation Analysis]
18 Long F, Dong C, Jiang K, Xu Y, Chi X, Sun D, Liang R, Gao Z, Shao S, Wang L. Melatonin enhances the anti-tumor effect of sorafenib via AKT/p27-mediated cell cycle arrest in hepatocarcinoma cell lines. RSC Adv 2017;7:21342-51. [DOI: 10.1039/c7ra02113e] [Cited by in Crossref: 9] [Article Influence: 1.8] [Reference Citation Analysis]
19 Wang R, Liu Y, Mi X, Chen Q, Jiang P, Hou J, Lin Y, Li S, Ji B, Fang Y. Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial dysfunction. Arch Biochem Biophys 2020;689:108415. [PMID: 32562663 DOI: 10.1016/j.abb.2020.108415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Shi Y, Huang A. Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs. Tumor Biol 2015;36:8455-63. [DOI: 10.1007/s13277-015-3565-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
21 Chi G, Pei J, Li X, Li X, Pang H, Cui J, Wu D, Qu G, He Y. SMYD5 acts as a potential biomarker for hepatocellular carcinoma. Exp Cell Res 2022;:113076. [PMID: 35218722 DOI: 10.1016/j.yexcr.2022.113076] [Reference Citation Analysis]
22 Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, François C, Chatelain D, Debuysscher V, Barbare JC, Chauffert B, Galmiche A. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett 2015;356:971-7. [PMID: 25444922 DOI: 10.1016/j.canlet.2014.11.014] [Cited by in Crossref: 116] [Cited by in F6Publishing: 118] [Article Influence: 14.5] [Reference Citation Analysis]
23 Saidak Z, Giacobbi A, Louandre C, Sauzay C, Mammeri Y, Galmiche A. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells. Cancer Letters 2017;392:1-8. [DOI: 10.1016/j.canlet.2017.01.038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
24 Shao W, Zhu W, Lin J, Luo M, Lin Z, Lu L, Jia H, Qin L, Lu M, Chen J. Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR. Neoplasia 2020;22:1-9. [PMID: 31751859 DOI: 10.1016/j.neo.2019.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Sun X, Niu X, Chen R, He W, Chen D, Kang R, Tang D. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 2016;64:488-500. [PMID: 27015352 DOI: 10.1002/hep.28574] [Cited by in Crossref: 167] [Cited by in F6Publishing: 174] [Article Influence: 27.8] [Reference Citation Analysis]
26 Faloppi L, Puzzoni M, Casadei Gardini A, Silvestris N, Masi G, Marisi G, Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas L, Lai E, Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A, Cascinu S, Scartozzi M. Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targ Oncol 2020;15:115-26. [DOI: 10.1007/s11523-020-00698-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
27 Gao X, Tang M, Tian S, Li J, Liu W. A ferroptosis-related gene signature predicts overall survival in patients with lung adenocarcinoma. Future Oncol 2021;17:1533-44. [PMID: 33432837 DOI: 10.2217/fon-2020-1113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
28 da Motta Girardi D, Correa TS, Crosara Teixeira M, Dos Santos Fernandes G. Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. J Gastrointest Canc 2018;49:227-36. [DOI: 10.1007/s12029-018-0121-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
29 Yu H, Guo P, Xie X, Wang Y, Chen G. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med 2017;21:648-57. [PMID: 27860262 DOI: 10.1111/jcmm.13008] [Cited by in Crossref: 154] [Cited by in F6Publishing: 159] [Article Influence: 25.7] [Reference Citation Analysis]
30 Deng T, Hu B, Jin C, Tong Y, Zhao J, Shi Z, Zhang T, Deng L, Sun Z, Chen G, Wang Y. A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma. J Cell Mol Med 2021;25:6618-33. [PMID: 34085405 DOI: 10.1111/jcmm.16666] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
31 Yu J, Wang N, Gong Z, Liu L, Yang S, Chen GG, Lai PBS. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma. Oncogene 2021;40:492-507. [PMID: 33184472 DOI: 10.1038/s41388-020-01545-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
32 Gozdecka M, Lyons S, Kondo S, Taylor J, Li Y, Walczynski J, Thiel G, Breitwieser W, Jones N. JNK Suppresses Tumor Formation via a Gene-Expression Program Mediated by ATF2. Cell Reports 2014;9:1361-74. [DOI: 10.1016/j.celrep.2014.10.043] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
33 Wu D, Chen L. Ferroptosis: a novel cell death form will be a promising therapy target for diseases. Acta Biochim Biophys Sin (Shanghai) 2015;47:857-9. [PMID: 26350095 DOI: 10.1093/abbs/gmv086] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
34 Lachaier E, Louandre C, Ezzoukhry Z, Godin C, Mazière J, Chauffert B, Galmiche A. La ferroptose, une nouvelle forme de mort cellulaire applicable au traitement médical des cancers. Med Sci (Paris) 2014;30:779-83. [DOI: 10.1051/medsci/20143008016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
35 Lai Y, Zhang Z, Li J, Li W, Huang Z, Zhang C, Li X, Zhao J. STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma. Biochem Biophys Res Commun 2019;519:659-66. [PMID: 31542233 DOI: 10.1016/j.bbrc.2019.09.032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
36 Zhang L, Jia R, Li H, Yu H, Ren K, Jia S, Li Y, Wang Q. Insight into the Double-Edged Role of Ferroptosis in Disease. Biomolecules 2021;11:1790. [PMID: 34944434 DOI: 10.3390/biom11121790] [Reference Citation Analysis]
37 Houessinon A, François C, Sauzay C, Louandre C, Mongelard G, Godin C, Bodeau S, Takahashi S, Saidak Z, Gutierrez L, Régimbeau JM, Barget N, Barbare JC, Ganne N, Chauffert B, Coriat R, Galmiche A. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib. Mol Cancer 2016;15:38. [PMID: 27184800 DOI: 10.1186/s12943-016-0526-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 7.7] [Reference Citation Analysis]
38 Li Y, Zhang J, Zhang K, Chen Y, Wang W, Chen H, Zou Z, Li Y, Dai M. Scutellaria barbata Inhibits Hepatocellular Carcinoma Tumorigenicity by Inducing Ferroptosis of Hepatocellular Carcinoma Cells. Front Oncol 2022;12:693395. [DOI: 10.3389/fonc.2022.693395] [Reference Citation Analysis]
39 Nie J, Lin B, Zhou M, Wu L, Zheng T. Role of ferroptosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2018;144:2329-37. [PMID: 30167889 DOI: 10.1007/s00432-018-2740-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 8.3] [Reference Citation Analysis]
40 Cong WM, Wu MC. New insights into molecular diagnostic pathology of primary liver cancer: Advances and challenges. Cancer Lett 2015;368:14-9. [PMID: 26276723 DOI: 10.1016/j.canlet.2015.07.043] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
41 Denorme M, Yon L, Roux C, Gonzalez BJ, Baudin E, Anouar Y, Dubessy C. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model. Cancer Lett 2014;352:236-44. [PMID: 25016061 DOI: 10.1016/j.canlet.2014.07.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
42 Liu H, Wang X, Shi G, Jiang L, Liu X. Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo. Tumor Biol 2014;35:8249-58. [DOI: 10.1007/s13277-014-2083-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Avila M, Berasain C. Making sorafenib irresistible: In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14. Hepatology 2015;61:1755-7. [PMID: 25677471 DOI: 10.1002/hep.27739] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
44 Yang J, Xu J, Zhang B, Tan Z, Meng Q, Hua J, Liu J, Wang W, Shi S, Yu X, Liang C. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. Int J Mol Sci 2021;22:10944. [PMID: 34681603 DOI: 10.3390/ijms222010944] [Reference Citation Analysis]
45 Wei Y, Lv H, Shaikh AB, Han W, Hou H, Zhang Z, Wang S, Shang P. Directly targeting glutathione peroxidase 4 may be more effective than disrupting glutathione on ferroptosis-based cancer therapy. Biochim Biophys Acta Gen Subj 2020;1864:129539. [PMID: 31958545 DOI: 10.1016/j.bbagen.2020.129539] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
46 Sauzay C, Louandre C, Bodeau S, Anglade F, Godin C, Saidak Z, Fontaine JX, Usureau C, Martin N, Molinie R, Pascal J, Mesnard F, Pluquet O, Galmiche A. Protein biosynthesis, a target of sorafenib, interferes with the unfolded protein response (UPR) and ferroptosis in hepatocellular carcinoma cells. Oncotarget 2018;9:8400-14. [PMID: 29492203 DOI: 10.18632/oncotarget.23843] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
47 Li Y, Xia J, Shao F, Zhou Y, Yu J, Wu H, Du J, Ren X. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis. Biochem Biophys Res Commun 2021;534:877-84. [PMID: 33162029 DOI: 10.1016/j.bbrc.2020.10.083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
48 Cheng CC, Chao WT, Liao CC, Tseng YH, Lai YC, Lai YS, Hsu YH, Liu YH. Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment. Cell Adh Migr 2018;12:19-27. [PMID: 28276928 DOI: 10.1080/19336918.2017.1288789] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]